In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

D. Medical Industries, Ltd.

http://dmedicalindustries.com/

Latest From D. Medical Industries, Ltd.

Consumers’ Inflation Fatigue, Recession Fears May Put Health, Beauty Product Price Increases On Hold

Church & Dwight, Perrigo executives' comments at investor conferences could signal OTC drug, supplement and personal care product firms are moving from gauging pandemic impact on supply chains and consumer spending to anticipating shifts in consumer preferences and cost increases caused by inflation with recession appearing more likely every day.

Consumer Coronavirus COVID-19

Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims

NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.

Ad Complaints Dietary Supplements

Church & Dwight ‘Left Money On Table’ In Q1, Same Supply Chain Problems Expected Q2 Before Easing

“We have the orders, we’re just struggling to fill them either due to production problems or transportation issues,” says CEO Matthew Farrell.

Sales & Earnings Supply Chain

US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results

Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.

Consumer Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
  • Miscellaneous
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • In Vitro Diagnostics
    • Glucose Testing
  • Other Names / Subsidiaries
    • D-Medical
UsernamePublicRestriction

Register